Atea Pharmaceuticals AVIR
NASDAQ AVIR
$4.22 +0.02 (+0.48%)
At close: Nov 11, 2026 · 4:00 PM EST

Atea Pharmaceuticals (AVIR) Receivables (2021 - 2022)

Updated

Atea Pharmaceuticals (AVIR) reported Receivables of $4.51 million for Q3 2022.

Analysis

Atea Pharmaceuticals (AVIR) Receivables (2021 - 2022) Analysis & Trends

  • The Q3 2022 figure ranks as the highest quarterly Receivables since Q2 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 25.23 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 18.99 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 13.51 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 12.74 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 16.16 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 10.35 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 5.01 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 14.19 Bn
10 Atea Pharmaceuticals 337.28 Mn -631.22 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 4.51 Mn
Jun 30, 2021 50.00 Mn
API Access

Atea Pharmaceuticals Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=AVIR&period=max&api_key=YOUR_API_KEY